Vigonvita Life Sciences Co., Ltd. operates as biopharmaceutical company. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2025-11-06. The firm mainly focuses on the fields of neuropsychiatric, reproductive health and viral infection treatment. The firm's product pipeline mainly includes LV232, TPN102, VV119, VV147, TPN171, VV913, VV116, VV261 and VV207. The firm has entered the commercialization stage. The firm primarily operates its businesses in China and Uzbekistan.